Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape

/in , , , , , /by

Dr. Nazarian's lab

PDF Version

What’s Known
Fewer than 150 U.S. children per year are diagnosed with diffuse intrinsic pontine glioma (DIPG), one of the most lethal pediatric central nervous system cancers. Despite an increasing number of experimental therapies tested via clinical trials, more than 95 percent of these children die within two years of diagnosis. Molecular studies have yielded additional insight about DIPG, including that mutations in histone-encoding genes are associated with 70 percent of cases. Understanding mutations that drive tumors and the genomic landscape can help to guide development of targeted therapies.

What’s New: Frequently found genetic alterations prevalent in DIPGs

dipg-gene-mutations-and-biological-consequences

Source: “Clinicopathology of Diffuse Intrinsic Pontine Glioma and Its Redefined Genomic and Epigenomic Landscape.” E. Panditharatna, K. Yaeger, L.B. Kilburn, R.J. Packer, and J. Nazarian. Published by Cancer Genetics on May 1, 2015.
You might also like
Javad Nazarian Children’s National launches Open DIPG Initiative
proton center Johns Hopkins Proton Therapy Center opens in collaboration with Children’s National
photos used for facial analysis technology Facial analysis technology successful in identifying Williams-Beuren syndrome in diverse populations
germ cells in testicular tissues Experimental fertility preservation provides hope for young men
Test tube with DNA “Liquid biopsies” could track diffuse midline gliomas
Dr. Bornhorst talks with her patient Maddox Gibson, A melanoma drug shows promise for NF1 plexiforms